Immunotherapy has revolutionized the treatment of cancer but patient outcomes are incredibly diverse. The session "Immunotherapy Biomarkers" is dedicated to finding and utilizing biomarkers that can predict response, inform therapy choice, and enhance outcomes in cancer treatment.".
Immunotherapy biomarkers encompass tumor mutational burden, PD-L1 expression, tumor-infiltrating immune cells, cytokine profiles, and particular genetic or epigenetic signatures. Such markers assist clinicians in identifying which patients are more likely to gain a benefit from immune-based therapies and adjusting treatment strategies accordingly. Predictive biomarkers' early detection also facilitates monitoring of response, therapy modification, and management of possible adverse effects.
The session discusses the developments in molecular profiling, high-throughput sequencing, and computational technologies that allow accurate biomarker identification. Mapping of biomarker data with clinical data allows personalized treatment, maximizes efficacy, and minimizes unnecessary toxicity. New research continues to identify new biomarkers that improve patient stratification and guide combination therapy strategies.
Participants will learn about the biology, clinical use, and future prospects of immunotherapy biomarkers. This session highlights the key importance of biomarkers in maximizing the effectiveness of immunotherapy, directing precision oncology, and ultimately maximizing patient survival and quality of life.
Welcome to the Cancer and Oncology Conference 2026, where global researchers, clinicians, and academics meet to share advances in cancer biology, precision medicine, diagnostics, therapies, and global solutions for patient care.
